P. Roberts
Molecular Biology · with Der · 2007
A researcher in the Science corpus: 1 paper; trusts 4 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 26 citations into it; #10,277 of 17,773 by trust here, #12,742 by citations
- Oncology — 19 citations into it
- Pulmonary and Respiratory Medicine — 8 citations into it
- Pathology and Forensic Medicine — 6 citations into it
- Cancer Research — 5 citations into it
- Genetics — 5 citations into it
Whom P. Roberts trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- M. Karin
- Y. Yarden
- Walter Kolch
- J. Baselga
- J. Mendelsohn
- R. Shaw
- M. Scaltriti
- Marcos Malumbres
- Seunghee Yoon
- Anthony M. Manning
Who trusts P. Roberts overall
Papers from P. Roberts's perspective
Ordered by how strongly the researchers P. Roberts trusts endorse each paper. Same corpus, a different order for every researcher.
- Mutations of the BRAF gene in human cancer (Nature)
- Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
- Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. (Journal of Clinical Oncology)
- BRAF mutation predicts sensitivity to MEK inhibition (Nature)
- The RAF proteins take centre stage (Nature reviews. Molecular cell biology)
- Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status (Nature)
- Ras, PI(3)K and mTOR signalling controls tumour cell growth (Nature)
- Nuclear factor-κB in cancer development and progression (Nature)
- RAS oncogenes: the first 30 years (Nature Reviews. Cancer)
- Coordinating ERK/MAPK signalling through scaffolds and inhibitors (Nature reviews. Molecular cell biology)
Their papers
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007) — 2,862 citations